Successful EU MAA Submission Enabled By U.S.–EU Regulatory Collaboration

Submitting an EU Marketing Authorization Application (MAA) on time requires more than regulatory expertise—it demands seamless coordination across regions, evolving datasets, and compressed timelines. In this case study, Veristat helped a biopharmaceutical company successfully navigate a high-stakes EU MAA submission for a non-small cell lung cancer therapy by integrating complex FDA review outcomes into a globally aligned EMA dossier under a fixed submission deadline. Veristat’s regulatory, medical writing, publishing, pharmacovigilance, and quality teams rapidly adapted content to EMA expectations, developed critical Module 1 and labeling materials, and provided the infrastructure necessary to serve as the EU Marketing Authorization Applicant. Learn more from Veristats ' results, which demonstrate how integrated global regulatory support can help biopharma sponsors reduce submission risk, maintain momentum, and accelerate access to international markets.